Literature DB >> 25668639

Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT.

Massimiliano Pacilio1, Ernesto Amato, Nico Lanconelli, Chiara Basile, Leonel Alberto Torres, Francesca Botta, Mahila Ferrari, Nestor Cornejo Diaz, Marco Coca Perez, María Fernández, Michael Lassmann, Alex Vergara Gil, Marta Cremonesi.   

Abstract

This study compares 3D dose distributions obtained with voxel S values (VSVs) for soft tissue, calculated by several methods at their current state-of-the-art, varying the degree of image blurring. The methods were: 1) convolution of Dose Point Kernel (DPK) for water, using a scaling factor method; 2) an analytical model (AM), fitting the deposited energy as a function of the source-target distance; 3) a rescaling method (RSM) based on a set of high-resolution VSVs for each isotope; 4) local energy deposition (LED). VSVs calculated by direct Monte Carlo simulations were assumed as reference. Dose distributions were calculated considering spheroidal clusters with various sizes (251, 1237 and 4139 voxels of 3 mm size), uniformly filled with (131)I, (177)Lu, (188)Re or (90)Y. The activity distributions were blurred with Gaussian filters of various widths (6, 8 and 12 mm). Moreover, 3D-dosimetry was performed for 10 treatments with (90)Y derivatives. Cumulative Dose Volume Histograms (cDVHs) were compared, studying the differences in D95%, D50% or Dmax (ΔD95%, ΔD50% and ΔDmax) and dose profiles.For unblurred spheroidal clusters, ΔD95%, ΔD50% and ΔDmax were mostly within some percents, slightly higher for (177)Lu with DPK (8%) and RSM (12%) and considerably higher for LED (ΔD95% up to 59%). Increasing the blurring, differences decreased and also LED yielded very similar results, but D95% and D50% underestimations between 30-60% and 15-50%, respectively (with respect to 3D-dosimetry with unblurred distributions), were evidenced. Also for clinical images (affected by blurring as well), cDVHs differences for most methods were within few percents, except for slightly higher differences with LED, and almost systematic for dose profiles with DPK (-1.2%), AM (-3.0%) and RSM (4.5%), whereas showed an oscillating trend with LED.The major concern for 3D-dosimetry on clinical SPECT images is more strongly represented by image blurring than by differences among the VSVs calculation methods. For volume sizes about 2-fold the spatial resolution, D95% and D50% underestimations up to about 60 and 50% could result, so the usefulness of 3D-dosimetry is highly questionable for small tumors, unless adequate corrections for partial volume effects are adopted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25668639     DOI: 10.1088/0031-9155/60/5/1945

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  9 in total

1.  What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy.

Authors:  Johannes Tran-Gia; Maikol Salas-Ramirez; Michael Lassmann
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

2.  Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.

Authors:  C Chiesa; M Mira; M Maccauro; C Spreafico; R Romito; C Morosi; T Camerini; M Carrara; S Pellizzari; A Negri; G Aliberti; C Sposito; S Bhoori; A Facciorusso; E Civelli; R Lanocita; B Padovano; M Migliorisi; M C De Nile; E Seregni; A Marchianò; F Crippa; V Mazzaferro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

3.  The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.

Authors:  Alexander S Pasciak; Godwin Abiola; Robert P Liddell; Nathan Crookston; Sepideh Besharati; Danielle Donahue; Richard E Thompson; Eric Frey; Robert A Anders; Matthew R Dreher; Clifford R Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-18       Impact factor: 9.236

4.  3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.

Authors:  David Sarrut; Jean-Noël Badel; Adrien Halty; Gwenaelle Garin; David Perol; Philippe Cassier; Jean-Yves Blay; David Kryza; Anne-Laure Giraudet
Journal:  EJNMMI Phys       Date:  2017-01-18

5.  Impact of the dosimetry approach on the resulting 90Y radioembolization planned absorbed doses based on 99mTc-MAA SPECT-CT: is there agreement between dosimetry methods?

Authors:  Verónica Morán; Elena Prieto; Lidia Sancho; Macarena Rodríguez-Fraile; Leticia Soria; Arantxa Zubiria; Josep M Martí-Climent
Journal:  EJNMMI Phys       Date:  2020-12-07

Review 6.  Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects.

Authors:  Rachele Danieli; Alessia Milano; Salvatore Gallo; Ivan Veronese; Alessandro Lascialfari; Luca Indovina; Francesca Botta; Mahila Ferrari; Alessandro Cicchetti; Davide Raspanti; Marta Cremonesi
Journal:  J Pers Med       Date:  2022-02-02

7.  Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters.

Authors:  Yaser H Gholami; Kathy P Willowson; Dale L Bailey
Journal:  EJNMMI Phys       Date:  2022-07-30

Review 8.  Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer.

Authors:  Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis
Journal:  Diagnostics (Basel)       Date:  2022-07-21

9.  SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: Application to treatment response.

Authors:  Peter S Potrebko; Ravi Shridhar; Matthew C Biagioli; William F Sensakovic; George Andl; Jan Poleszczuk; Timothy H Fox
Journal:  J Appl Clin Med Phys       Date:  2018-07-01       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.